NASDAQ:CASI - CASI Pharmaceuticals, Inc.
$3.07
 $-0.03
-0.97%
12:15PM EDT
2019-07-22
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CASI     avg for
industry  
  avg for
sector  
42 stocks weight:  4. 05   217. 37   399. 45  
42 stocks rank:  4. 32 K 1. 27 K 716. 99  
# analyst opinions:  1. 00   13. 21   13. 71  

quick ratio:  20. 12   5. 49   1. 88  
current ratio:  21. 52   5. 87   2. 36  

target price low:  7. 00   83. 44   114. 90  
target price avg:  7. 00   106. 20   137. 90  
target price high:  7. 00   132. 30   158. 97  
1-yr high:  8. 08   111. 86   142. 57  
last close:  3. 10   86. 79   125. 44  
50-day avg:  3. 14   86. 68   122. 63  
200-day avg:  3. 46   89. 22   121. 38  
1-yr low:  2. 77   69. 78   100. 51  
volume:  77. 76 K 2. 62 M 3. 43 M
50-day avg volume:  152. 33 K 3. 20 M 4. 16 M
200-day avg volume:  260. 14 K 2. 99 M 4. 75 M

1-day return:  -1. 27 % -1. 30 % -0. 99 %
this week return:  -2. 21 % 0. 45 % -0. 20 %
12-wk return:  -9. 88 % 0. 94 % 4. 84 %
52-wk return:  -57. 05 % -1. 30 % 10. 55 %

enterprise value (EV):  220. 51 M 45. 10 B 122. 38 B
market cap:  296. 72 M 38. 96 B 108. 40 B
EBITDA:  -29. 90 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -7. 38   5. 38   11. 93  
total debt:  4. 46 M 10. 90 B 17. 48 B
debt/equity:  3. 59   57. 18   120. 05  
net income (common):  -32. 04 M 2. 07 B 4. 05 B

shares outstanding:  95. 72 M 538. 09 M 1. 24 B
shares:  35. 28 M 548. 00 M 1. 22 B
shares short:  4. 61 M 10. 98 M 11. 87 M
shares short prior month:  4. 80 M 9. 32 M 12. 05 M
short ratio:  25. 58   5. 60   3. 34  
short % of float:  9. 22 % 6. 48 % 2. 64 %
total cash/share:  1. 05   10. 98   9. 19  
total cash:  100. 69 M 5. 93 B 6. 10 B
free cash flow:  -19. 28 M 2. 92 B 4. 55 B
operating cash flow:  -27. 84 M 3. 80 B 5. 78 B

book value:  1. 09   13. 35   27. 45  
price/book:  2. 85   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 35   2. 10   4. 23  
forward EPS:  -0. 16   3. 45   7. 10  
P/E:  -8. 78   1. 90   32. 10  
forward P/E:  -19. 38   6. 46   15. 47  
PE/G:  2. 18   0. 70   -0. 54  
growth:  -4. 03 % 265. 63 % 79. 11 %
earnings high:  -0. 09   0. 89   1. 68  
earnings avg:  -0. 09   0. 70   1. 57  
earnings low:  -0. 09   0. 46   1. 46  
revenue high:  850. 00 K 2. 57 B 11. 07 B
revenue avg:  850. 00 K 2. 51 B 10. 91 B
revenue low:  850. 00 K 2. 45 B 10. 73 B
return on assets:  -19. 64 % -2. 34 % 5. 28 %
return on equity:  -33. 40 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  1. 37   1. 27   0. 91  
sharpe (1yr):  -0. 92   0. 16   0. 77  

held % insiders:  41. 36 % 6. 06 % 3. 29 %
held % institutions:  21. 00 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : CASI
.    101.434 =       101.434 :: --> INITIAL WEIGHT <--
.    - 0.353 =       101.081 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 2.229 =       225.313 :: P/E factor
.    x 0.936 =       210.817 :: PE/G factor
.    x 1.693 =       357.006 :: beta factor
.    x 0.971 =       346.649 :: sharpe factor
.    x 3.804 =      1318.823 :: current ratio factor
.    x 1.026 =      1352.868 :: quick ratio factor
.    x 1.019 =      1379.058 :: short ratio factor
.    x 1.027 =      1416.588 :: price-to-book factor
.    x 1.031 =      1460.367 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      3097.137 :: sector+industry 1-year gains factor
.    x 1.009 =      3126.337 :: industry 12-weeks return factor
.    x 1.308 =        4088.9 :: industry 2-weeks return factor
.    x 1.032 =      4221.096 :: 5-day avg > 50-day avg
.    x 0.987 =      4168.051 :: "drift" penalty 4 days ago
.    / 1.941 =      2147.545 :: overall "drift" factor
.    x 0.955 =      2050.395 :: largest single-day jump factor
.    x 0.071 =       145.625 :: low price factor
.    x 0.504 =        73.434 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.026 =          1.88 :: forward EPS factor
.    x 0.646 =         1.214 :: forward P/E factor
.    x 1.185 =         1.439 :: industry recommendation factor
.    x 1.003 =         1.443 :: factor historical industry gain for week 29
.   x 11.348 =         16.37 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         2.011 :: reduced for readability
.    + 2.034 =         4.046 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      4.046 :: FINAL WEIGHT for NASDAQ:CASI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org